FDA Approves New Drug Reflecting Cutting-Edge, ‘Tissue-Agnostic’ Effort to Beat Cancer

November 30, 2018

(USA Today) – A cutting-edge cancer treatment focusing on genetic biomarkers rather than any specific type of cancer won accelerated approval from the Food and Drug Administration. The approval this week for Vitrakvi, the brand name for larotrectinib, marks an emerging method for developing cancer drugs that are “tissue-agnostic” – drugs that are not specific to one organ such as the colon or breast.

Recommended Reading